# Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Source: https://onco.cc/trials/nct06584032/  
OnCo record `nct06584032` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Fruquintinib, Sintilimab, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Hutchmed, now recruiting.

## Summary

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer is a phase 3 interventional study registered as NCT06584032 by Hutchmed, with 412 participants planned, started 2024-12-12 and due to reach its primary completion in 2029-01-08. Interventions recorded: fruquintinib, sintilimab, paclitaxel, doxorubicin. Conditions listed: Advanced Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06584032
- Phase: 3
- Setting: A Randomized,Open-label,Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab Versus Chemotherapy of the Treating Physician's Choice as Second-line Treatment for Advanced Endometrial Cancer
- Sponsor: Hutchmed
- Enrolled: 412

## Sources

- ClinicalTrials.gov NCT06584032: https://clinicaltrials.gov/study/NCT06584032

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/nct06584032.json